1月13日,强生公司正在探索收购Intra-Cellular Therapies的可能性,一家专注于中枢神经系统疾病治疗的生物制药公司。此举可能是一年多来最大的生物技术交易,Intra-Cellular的市值在最近飙升后约为100亿美元。讨论仍在进行中,没有确定的交易,但此次收购可能会打破2024年重大生物技术交易的干旱。对Intra-Cellular的兴趣是在该公司上周五解决了知识产权悬而未决的...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.